Pharmacy & Therapeutics- July 2008 - (Page 414) CONTINUING EDUCATION CREDIT 98. Lane PL, McLellan BA, Baggoley CJ. Comparative efficacy of chlorpromazine and meperidine with dimenhydrinate in migraine headache. Ann Emerg Med 1989;18(4):361–365. 99. Gallagher MR. Emergency treatment of intractable migraine. Headache 1985;26:74–75. 100. Fisher MA, Glass S. Butorphanol (Stadol): A study in problems of current drug information and control. Headache 1997;48:1156–1160. 101. Hoffert MJ, Couch JR, Diamond S, et al. Transnasal butorphanol in the treatment of acute migraine. Headache 1995;35:65–69. 102. Biondi DM. Opioid resistance in chronic daily headache: A synthesis of ideas from the bench and bedside. Curr Pain Headache Rep 2003;7(1):67–75. 103. Edmeads J. Analgesic-induced headaches: An unrecognized epidemic. Headache 1990:614. 104. Diamond S, Medina JL, Isometheptene: A non-ergot drug in the treatment of migraine. Headache 1975;15:211–213. 105. Yuill GM, Swinburn WR, Liversedge LA. A double-blind cross-over trial of isometheptene mucate compound and ergotamine in migraine. Br J Clin Pract 1972;26:76–79. 106. Diamond S. Treatment of migraine with isometheptene, acetaminophen, and dichloralphenazone combination: A double-blind, crossover trial. Headache 1976;15:282–287. 107. Freitag FG, Cady R, DiSerio F, et al. Comparative study of a combination of isometheptene mucate, dichloralphenazone with acetaminophen, and sumatriptan succinate in the treatment of migraine. Headache 2001;41(4):391–398. 108. Bigal ME, Rapoport AM, Sheftell FD, et al. Transforming migraine and medication overuse in a tertiary headache centre: Clinical characteristics and treatment. Cephalalgia 2004;24(6):4483–4490. 109. Micieli G, Manzoni GC, Granella F, et al. Clinical and epidemiological observations on drug abuse in headache patients. In: Diener HC, Wilkinson M, eds. Drug-Induced Headache. Heidelberg, Germany: Springer-Verlag; 1988:20–28. 110. Ferrari A, Savino G, Gallesi D, et al. Effects of overuse of the antimigraine combination of indomethacin, prochlorperazine and caffeine on the disposition of its components in chronic headache patients. Pharmacol Res 2006;54:142–149. 111. Paemeleire K, Crevits L, Goadsby PJ, et al. Practical management of medication-overuse headache. Acta Neurol Belg 2006;106(2): 43–51. 112. Freitag FG, Lake A, Lipton R, et al. Inpatient treatment of headaches: An evidence-based assessment. Headache 2004;44:342–360. 113. Raskin NH. Repetitive intravenous dihydroergotamine as therapy for intractable migraine. Neurology 1986;36:995–997. 114. Smith RS. Low-dose tizanidine with nonsteroidal anti-inflammatory drugs for detoxification from analgesic rebound headache. Headache 2002;42:175–177. 115. Zed PJ, Loewen PS, Robinson G. Medication-induced headache: Overview and systematic review of therapeutic approaches. Ann Pharmacother 1999;33:61–72. 116. Humphrey PP, Feniuk W, Perren MJ et al. Serotonin and migraine. Ann NY Acad Sci 1990;600:587–598. 117. Hoyer D, Clarke DE, Fozard JR, et al. International Union of Pharmacology classification of receptors for 5-hydroxytriptamine (serotonin). Pharmacol Rev 1994;46:157–203. 118. Hartig PR, Hoyer D, Humphrey PP, et al. Alignment of receptor nomenclature with the human genome: Classification of 5-HTIB and 5-HT1D receptor subtypes. Trends Pharmacol Sci 1996;17: 103–105. 119. Goldstein DJ, Roon KI, Offen WW, et al. Selective serotonin 1F (5-HT1F) receptor agonist LY334370 for acute migraine: A randomized controlled trial. Lancet 2001;358:1230–1234. 120. Peroutka SJ. Developments in 5-hydroxytriptamine receptor pharmacology in migraine. Neurol Clin 1990;8:829–839. 121. Siberstein SD. The pharmacology of ergotamine and dihydroergotamine. Headache 1997;36(Suppl 1):S15–S25. 122. Siberstein SD. Serotonin (5-HT) and migraine. Headache 1994;34: 408–417. 123. Peroutka SJ. 5-Hydroxytriptamine receptor subtypes and the pharmacology of migraine. Neurology 1993;43(Suppl 3):S34–S38. 124. Borne RF. Serotonin: the neurotransmitter for the 90’s. Drug Top 1994;10:108. 125. Deliganis AV, Peroutka SJ. 5-Hydroxytriptamine1D receptor agonism predicts antimigraine efficacy. Headache 1991;31(4):228–231. 126. Buzzi MG, Moskowitz MA. Evidence for 5-HT1B/1D receptors mediating the antimigraine effect of sumatriptan and dihydroergotamine. Cephalalgia 1991;11(4):165–168. 127. Scott AK. Dihydroergotamine: A review of its use in the treatment of migraine and other headaches. Clin Neuropharmacol 1992;15(4): 289–296. 128. Goldstein J. Ergot pharmacology and alternative delivery systems for ergotamine derivatives. Neurology 1992;42(Suppl 2):45–46. 129. Bigal ME, Tepper SJ. Ergotamine and dihydroergotamine: A review. Curr Pain Headache Rep 2003;7(1):55–62. 130. Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: Studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 1993;33:48–56. 131. Ward TN, Scott G. Dihydroergotamine suppositories in a headache clinic. Headache 1991;31(7):465–466. 132. Neuman M, Demarez JP, Harmey JL, et al. Prevention of migraine attacks through the use of dihydroergotamine. Int J Clin Pharmacol Res 1986;VI(1):11–13. 133. Young WB. Appropriate use of ergotamine tartrate and dihydroergotamine in the treatment of migraine: Current perspectives. Headache 1997;37(Suppl 1):S42–S45. 134. Callaham M, Raskin N. A controlled study of dihydroergotamine in the treatment of acute migraine headache. Headache 1986;26: 168–171. 135. Carleton SC, Shesser RF, Pietrzak MP, et al. Double-blind, multicenter trial to compare the efficacy of intramuscular dihydroergotamine plus hydroxyzine versus intramuscular meperidine plus hydroxyzine for the emergency treatment of acute migraine headaches. Am Emerg Med 1998;32:129–138. 136. Winner P, Ricalde O, Le Force B, et al. A double-blind study of subcutaneous dihydroergotamine vs. subcutaneous sumatriptan in the treatment of acute migraine. Arch Neurol 1996;53:180–184. 137. Colman I, Brown MD, Innes GD, et al. Parenteral dihydroergotamine for acute migraine headaches: A systemic review of the literature. Ann Emerg Med 2005;45(4):393–401. 138. Gallagher RM. Acute treatment of migraine with dihydroergotamine nasal spray. Arch Neurol 1996;53:1285–1291. 139. Ziegler D, Ford R, Kriegler J, et al. Dihydroergotamine nasal spray for the acute treatment of migraine. Neurology 1994;44:447–453. 140. Dihydroergotamine Nasal Spray Multicenter Investigators. Efficacy, safety, and tolerability of dihydroergotamine nasal spray as monotherapy in the treatment of acute migraine. Headache 1995; 35:177–184. 141. Touchon J, Bertin L, Pilgrim AJ, et al. A comparison of subcutaneous sumatriptan and dihydroergotamine nasal spray in the acute treatment of migraine. Neurology 1996;47:361–365. 142. Migranal (dihydroergotamine), package insert. East Hanover, NJ: Novartis; December 2001. 143. Schulman EA, Rosenberg SB. Claudication: An unusual side effect of DHE administration. Headache 1991;31(4):237–239. 144. Peters GA, Horton BT. Headache with special reference to the excessive use of ergotamine preparations and withdrawal effects. Mayo Clin Proc 1951;26:153–161. 145. Saper J. Ergotamine tartrate addiction. Mich Pharm 1986;4–8. 146. Saper J. Ergotamine dependency: A review. Headache 1987;27: 435–438. 147. Saper J, Jones JM. Ergotamine tartrate dependency: Features and possible mechanisms. Clin Neuropharmacol 1986;9(3):244–256. 148. Imitrex (sumatriptan), package insert. Research Triangle Park, NC: GlaxoSmithKline; 2006. 149. Zomig, ZMT, Nasal Spray (zolmitriptan), package insert. Wilmington, DE: AstraZeneca; 2006. 150. Amerge (naratriptan), package insert. Research Triangle Park, NC: GlaxoSmithKline; 2006. 151. Maxalt, Maxalt-MLT (rizatriptan), package insert. Whitehouse Station, NJ: Merck & Co.; 2007. 152. Axert (almotriptan), package insert. Raritan, NJ: Ortho-McNeil; 2006. 153 Frova (frovatriptan), package insert. Chadds Ford, PA: Endo; 2005. 154. Relpax (eletriptan), package insert. New York: Pfizer; 2006. 155. Burstein R, Jakubowski M. Analgesic triptan action in an animal model of intracranial pain. Ann Neurol 2004;55:27–36. 156. Coulte r DM, Passier JL, Clark DW, et al. Activation of pain by suma- 414 P&T® • July 2008 • Vol. 33 No. 7
For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.